Copyright
©The Author(s) 2017.
World J Gastroenterol. Apr 7, 2017; 23(13): 2396-2403
Published online Apr 7, 2017. doi: 10.3748/wjg.v23.i13.2396
Published online Apr 7, 2017. doi: 10.3748/wjg.v23.i13.2396
Figure 3 The changes of the Child-Turcotte-Pugh and model for end-stage liver disease scores in the decompensated group after tenofovir disoproxil fumarate treatment for 12 mo.
The mean Child-Turcotte-Pugh (CTP) score (8.0 ± 1.5 vs 6.3 ± 1.3) and model for end-stage liver disease (MELD) scores (13.4 ± 4.7 vs 10.5 ± 3.9) improved after 12 mo of tenofovir disoproxil fumarate treatment than at baseline (P < 0.001 for all). CTP: Child-Turcotte-Pugh; MELD: Model for End-stage Liver Disease.
- Citation: Lee SK, Song MJ, Kim SH, Lee BS, Lee TH, Kang YW, Kim SB, Song IH, Chae HB, Ko SY, Lee JD. Safety and efficacy of tenofovir in chronic hepatitis B-related decompensated cirrhosis. World J Gastroenterol 2017; 23(13): 2396-2403
- URL: https://www.wjgnet.com/1007-9327/full/v23/i13/2396.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i13.2396